JUPITER, FL, – Working with a group of national and international researchers, scientists from the Florida campus of The Scripps Research Institute have developed a new genetic model of premature aging disorders that could shed light on these rare conditions in humans and provide a novel platform for large-scale screening of compounds to combat these and other age-related diseases.
In the new study, which was published this month in the open-access publication PLoS ONE, the scientists found a way to use zebrafish (Danio rerio) to model two rare human genetic disorders: Hutchinson-Gilford Progeria Syndrome and laminopathies.
“This is a robust model system of human aging that corresponds directly to the human genes involved in these diseases,” said Scripps Florida Assistant Professor Shuji Kishi, who led the study. “This model is ready now and can be used to screen and develop chemical compounds to treat these and other age-related diseases.”
Kishi noted that zebrafish, which display an array of signs of aging resembling those in humans, have emerged over the past decade as a powerful system to study diseases associated with aging and development.
Hutchinson-Gilford Progeria Syndrome is a rare disease that causes symptoms of advanced aging such as cardiovascular problems, hair loss, and distressed skin in young children. The laminopathies are a cluster of at least 13 different genetic disorders, whose symptoms range from muscular dystrophy to premature aging. They are grouped together because they are all caused by mutations in the genes that encode proteins of the nuclear membrane, the double-hulled envelope that surrounds the cell nucleus.
The gene associated with both progeria and laminopathies is the lamin A gene (LMNA), which presumably is also involved in the normal process of human aging, although the underlying mechanisms of the process are still relatively unknown.
In the new research, scientists set out to block the protein production of the LMNA gene in zebrafish. This resulted in apoptosis or programmed cell death, as well as interruption of the normal cell cycle. Deletion of some specific amino acid residues in the lamin A protein also produced aging in embryonic zebrafish.
Intriguingly, the study also found that farnestyl transferase inhibitor (FTI), a new class of anti-cancer drugs, reduced abnormalities in the nuclear membrane and prevented significant aging in the embryonic zebrafish models, which survived to adulthood but with a shortened lifespan.
“Utilizing our ’embryonic senescence’ zebrafish model, our next goal will be to find modifier genes as well as chemical compounds to reverse accelerated aging and restore the normal aging process,” Kishi said. “These findings could contribute to healthy aging in normal individuals, because the moderate defects of lamin A are also associated with the normal aging process.”
The first author of the study, “Embryonic Senescence and Laminopathies in a Progeroid Zebrafish Model,” is Eriko Koshimizu of Harvard University and the Tokyo University of Marine Science and Technology. Other authors include Shintaro Imamura, Jamal Toure and Jun-ichi Hanai of Harvard University; Christopher E. Carr of the Massachusetts Institute of Technology; Jie Qi of Harvard University and The Scripps Research Institute; and Delgado M. Valdez Jr. of The Scripps Research Institute. See http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0017688 .
The work was supported by The Ellison Medical Foundation and The Glenn Foundation for Medical Research.
About The Scripps Research Institute
The Scripps Research Institute is one of the world’s largest independent, non-profit biomedical research organizations. Scripps Research is internationally recognized for its discoveries in immunology, molecular and cellular biology, chemistry, neuroscience, and vaccine development, as well as for its insights into autoimmune, cardiovascular, and infectious disease. Headquartered in La Jolla, California, the institute also includes a campus in Jupiter, Florida, where scientists focus on drug discovery and technology development in addition to basic biomedical science. Scripps Research currently employs about 3,000 scientists, staff, postdoctoral fellows, and graduate students on its two campuses. The institute’s graduate program, which awards Ph.D. degrees in biology and chemistry, is ranked among the top ten such programs in the nation. For more information, see www.scripps.edu.